Health Care Leaders Overwhelmingly Support Government Action To Curb Drug Costs: Survey
According to Modern Healthcare's latest survey of executives, 90 percent of CEOs polled say that the fast rise of prescription drug prices was undermining their company's finances. In related news, The Philadelphia Inquirer reports on cancer treatment costs that can reach $30,000 a month.
CEO Power Panel: Healthcare Leaders Back Feds Stepping In To Restrain Drug Prices
Nearly seven-eighths of the country's top healthcare leaders favor the government taking a bigger role in curbing the rising cost of prescription drugs, while nearly all say that the two-year runup in drug prices has hurt their bottom lines. A whopping 90% of CEOs responding to Modern Healthcare's latest CEO Power Panel survey said rising drug costs were undermining their finances. Nearly half (45%) said the impact was “very negative.” (Johnson, 11/14)
The Philadelphia Inquirer:
Examining The Cost Of Cancer Treatment
In addition to the medical and emotional toll, the financial cost of cancer can be overwhelming. On average, some of the newer drugs run to $10,000 a month, with some exceeding $30,000 a month, according to the American Society of Clinical Oncology, a group of about 35,000 cancer professionals. ASCO and another group, the National Comprehensive Cancer Network (NCCN), have begun developing guidelines and tools to help physicians, patients, and their families assess efficacy, toxicity, and costs of the various treatment options. (Bauers, 11/15)